Read More Pharma Industry News Atrium Therapeutics (Nasdaq: RNA) Q1 results show cash runway and clinical urgency behind precision cardiology bet Atrium has cash and RNA ambition. The harder test is whether heart-targeted delivery can turn rare cardiomyopathy science into clinical proof. byVenkateshMay 15, 2026